Keep up to date with the latest news and updates about the ABATED study
Alzheimer's Association International Conference 2023 20 July 2023
Festival of Communities 12 June 2023
First ABATED focus group 2 November 2022
AINOSTICS granted FDA Breakthrough Device Designation 8 September 2022
AINOSTICS has been awarded Breakthrough Device Designation by the US Food and Drug Administration (FDA) to the product, BR[AI]N.
Funding to evaluate AI technology for timely and equitable dementia diagnosis 9 May 2022
ABATED Study Funding Announcement